As a progressive freshman mayor, Johnson’s challenge now is to stand up for Chicago’s large immigrant community while also navigating the risks of antagonizing Trump.

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson can keep the GOP united by proposing a bill ending every Democrat-supported malady at once.

We recently published a list of Jim Cramer Discusses TikTok Ban, President Trump & These 6 Stocks. In this article, we are ...

A new Wall Street Journal report says there are a few reasons why a company might list a job, but never follow through and hire someone.

Companies are posting robust results so far this earnings season, but the bar is high for stock gains to continue.

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

Dueling moves by Trump and Biden open new frontiers for one of the most sweeping powers in the Constitution.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Loss of breadth: Check. A handful of technology giants-what UBS calls the 'Magnificent Six,' which excludes Tesla -are driving the market, while smaller stocks lag. The average 12-month forward ...

Johnson & Johnson (NYSE: JNJ) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 ...